+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Castrate-Resistant Prostate Cancer Market Report and Forecast 2024-2032

  • PDF Icon

    Report

  • 200 Pages
  • September 2023
  • Region: Global
  • Expert Market Research
  • ID: 5895162
Description Jump to:
The castrate resistant prostate cancer market was valued at USD 11.2 billion in 2023, driven by increasing collaboration among pharmaceutical companies. The market size is anticipated to grow at a CAGR of 8.7% during the forecast period of 2024-2032 to achieve a value of USD 23.5 billion by 2032.

Castrate Resistant Prostate Cancer: Introduction

Castration-resistant prostate cancer (CRPC) is a form of prostate cancer that no longer responds to medical or surgical interventions that lower testosterone levels in the body, such as surgical castration (removal of the testicles) or androgen deprivation therapy (ADT). Testosterone is a male hormone that can stimulate the growth of prostate cancer cells. When prostate cancer becomes resistant to these therapies, it can continue to grow and spread even in the absence of testosterone.

Key Trends in the Global Castrate Resistant Prostate Cancer Market

The castrate resistant prostate cancer market has been experiencing significant growth and evolution in recent years. Several key trends are some key trends shaping the market:

  • Emerging Therapies: New therapeutic options, including novel androgen receptor-targeted therapies, immunotherapies, and radiopharmaceuticals, are continuing to emerge. These treatments aim to provide improved efficacy and fewer side effects for CRPC patients.
  • Biomarker-Driven Treatment: Personalized medicine approaches are gaining prominence. Biomarker testing helps identify specific genetic mutations or protein markers that guide treatment decisions, ensuring patients receive therapies tailored to their unique molecular profiles.
  • Immunotherapy Advancements: Immune checkpoint inhibitors and other immunotherapies are being explored for their potential in treating CRPC. These therapies aim to harness the patient's immune system to target cancer cells.
  • Radiopharmaceuticals: Radiopharmaceuticals such as radium-223 (Xofigo) have been approved for the treatment of CRPC patients with bone metastases. This trend continues to evolve with the development of new agents.
  • Combination Therapies: Researchers and pharmaceutical companies are investigating combination therapies that target multiple pathways involved in CRPC simultaneously. This approach aims to enhance treatment efficacy and delay disease progression.

Castrate Resistant Prostate Cancer Market Segmentations

The market can be categorized into therapy type, therapy drug class, route of administration, distribution channel, and region.

Market Breakup by Therapy Type

  • Hormonal Therapy
  • Immunotherapy
  • Chemotherapy
  • Others

Market Breakup by Therapy Drug Class

  • Antineoplastic
  • Non-steroidal Antiandrogen
  • Corticosteroids
  • Others

Market Breakup by Route of Administration

  • Oral
  • Parenteral

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Market Breakup by Region -7MM

  • United States
  • EU-4 and the United Kingdom
  • Japan

Castrate Resistant Prostate Cancer Market Overview

The market for Castrate Resistant Prostate Cancer (CRPC) continues to be a significant and evolving aspect of the oncology landscape. CRPC, a stage of prostate cancer that no longer responds to hormone therapy, has seen notable advancements in diagnosis and treatment. Innovative therapies, including next-generation anti-androgens and immunotherapies, have been approved and are offering new hope to patients with CRPC. Additionally, molecular profiling and precision medicine approaches are gaining prominence in tailoring treatments to individual patients, enhancing their efficacy, and reducing side effects. Clinical trials are ongoing, exploring novel therapeutic modalities, combination therapies, and biomarker-driven interventions. The CRPC market remains dynamic, with a focus on improving patient outcomes, enhancing the quality of life, and extending survival for those affected by this challenging form of cancer. Collaboration among pharmaceutical companies, research institutions, and healthcare providers plays a pivotal role in advancing CRPC treatment options.

Key Players in the Castrate Resistant Prostate Cancer Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.

The major companies in the castrate resistant prostate cancer market are as follows:

  • Sanofi
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Astellas Pharma, Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Allergan
  • AstraZeneca
  • Cipla Inc.
  • Amneal Pharmaceuticals LLC
The publisher always strives to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Castrate-Resistant Prostate Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Castrate-Resistant Prostate Cancer Epidemiology Analysis-7MM
5.1 Epidemiology Overview (2017-2032)
5.2 United States Castrate-Resistant Prostate Cancer Epidemiology (2017-2032)
5.3 EU-4 and United Kingdom Castrate-Resistant Prostate Cancer Epidemiology (2017-2032)
5.4 Japan Castrate-Resistant Prostate Cancer Epidemiology (2017-2032)
6 Castrate-Resistant Prostate Cancer Market Overview
6.1 Castrate-Resistant Prostate Cancer Market Historical Value (2017-2023)
6.2 Castrate-Resistant Prostate Cancer Market Forecast Value (2024-2032)
7 Castrate-Resistant Prostate Cancer Market Landscape
7.1 Castrate-Resistant Prostate Cancer: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Castrate-Resistant Prostate Cancer: Product Landscape
7.2.1 Analysis by Therapy Type
7.2.2 Analysis by Drug Class
7.2.3 Analysis by Route of Administration
8 Castrate-Resistant Prostate Cancer Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Castrate-Resistant Prostate Cancer Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Castrate-Resistant Prostate Cancer Market Segmentation
11.1 Castrate-Resistant Prostate Cancer Market by Therapy Type
11.1.1 Market Overview
11.1.2 Hormonal Therapy
11.1.3 Immunotherapy
11.1.4 Chemotherapy
11.1.5 Others
11.2 Castrate-Resistant Prostate Cancer Market by Therapy Drug Class
11.2.1 Market Overview
11.2.2 Antineoplastic
11.2.3 Non-steroidal Antiandrogen
11.2.4 Corticosteroids
11.2.5 Others
11.3 Castrate-Resistant Prostate Cancer Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.4 Castrate-Resistant Prostate Cancer Market by Distribution Channel
11.4.1 Market Overview
11.4.2 Hospital Pharmacy
11.4.3 Retail Pharmacy
11.4.4 Online Pharmacy
11.5 Castrate-Resistant Prostate Cancer Market by Region -7MM
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.4 Japan
12 United States Castrate-Resistant Prostate Cancer Market
12.1 U.S. Castrate-Resistant Prostate Cancer Market Historical Size (2017-2023)
12.2 U.S. Castrate-Resistant Prostate Cancer Market Forecast Size (2024-2032)
12.3 Market Size by Therapeutic Class
13 EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market
13.1 EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market Historical Size (2017-2023)
13.2 EU-5 and the United Kingdom Castrate-Resistant Prostate Cancer Market Forecast Size (2024-2032)
13.3 Market Size by Therapeutic Class
14 Japan Castrate-Resistant Prostate Cancer Market
14.1 Japan Castrate-Resistant Prostate Cancer Market Historical Size (2017-2023)
14.2 Japan Castrate-Resistant Prostate Cancer Market Forecast Size (2024-2032)
14.3 Market Size by Therapeutic Class
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Sanofi
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Johnson & Johnson Services Inc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Pfizer Inc.
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 Astellas Pharma, Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Bayer AG
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 F. Hoffmann-La Roche Ltd.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Mylan N.V.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Teva Pharmaceutical Industries Ltd.
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 GlaxoSmithKline plc
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Novartis AG
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Eli Lilly and Company
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Merck & Co., Inc.
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Allergan
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 AstraZeneca
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 Cipla Inc.
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
21.16 Amneal Pharmaceuticals LLC
21.16.1 Financial Analysis
21.16.2 Product Portfolio
21.16.3 Demographic Reach and Achievements
21.16.4 Mergers and Acquisitions
21.16.5 Certifications
22 Castrate-Resistant Prostate Cancer - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket

Companies Mentioned

  • Sanofi
  • Johnson & Johnson Services Inc.
  • Pfizer Inc.
  • Astellas Pharma, Inc.
  • Bayer AG
  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Allergan
  • AstraZeneca
  • Cipla Inc.
  • Amneal Pharmaceuticals LLC

Methodology

Loading
LOADING...

Related Topics

Related Reports

Castrate-resistant Prostate Cancer (CRPC) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Castrate-resistant Prostate Cancer (CRPC) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Castrate-Sensitive Prostate Cancer (CSPC) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Castrate-Sensitive Prostate Cancer (CSPC) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Prostate Cancer Treatment Market Size and Forecast 2020 - 2030, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Therapy Type, End Users, and Geography - Product Image

Prostate Cancer Treatment Market Size and Forecast 2020 - 2030, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Therapy Type, End Users, and Geography

  • Report
  • 150 Pages
  • Global
From
Prevention and Treatment of Prostate Cancer: Technologies and Global Markets - Product Image

Prevention and Treatment of Prostate Cancer: Technologies and Global Markets

  • Report
  • 157 Pages
  • Global
From
Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2024-2028 - Product Image

Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2024-2028

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.